Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
RXST Analyst Ratings
Hold
4 Buy
3 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RXST Stock 12 Month Forecast
Average Price Target
$22.56
▲(50.00%Upside)
| Highest Price Target$42.00 | Average Price Target$22.56 | Lowest Price Target$16.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$15
Hold
-0.27%
Downside
Reiterated
06/05/25
The overall stock score is primarily influenced by financial performance, with strong revenue growth offset by profitability and cash flow challenges. Technical analysis indicates a bearish trend, while valuation is hindered by ongoing losses and no dividend yield. Despite positive customer sentiment and European regulatory approval, revised revenue guidance lowers near-term outlook.
Wells Fargo
$25
Buy
66.22%
Upside
Reiterated
05/30/25
Piper Sandler
$18
Hold
19.68%
Upside
Reiterated
05/08/25
Bank of America Securities
$22→$18
Sell
19.68%
Upside
Reiterated
05/08/25
Needham
$22
Buy
46.28%
Upside
Reiterated
05/08/25
Stifel Nicolaus
$28→$17
Hold
13.03%
Upside
Reiterated
05/08/25
BTIG
$28
Buy
86.17%
Upside
Reiterated
05/07/25
UBS
$45→$16
Hold
6.38%
Upside
Downgraded
04/09/25
J.P. Morgan
$40→$17
Sell
13.03%
Upside
Downgraded
04/03/25
Morgan Stanley
$42
Buy
179.26%
Upside
Reiterated
04/03/25
Jefferies
$50
Buy
232.45%
Upside
Reiterated
03/03/25
Promising Growth and Competitive Edge: A Buy Rating for RxSightWe recently met with RXST management at their HQ, including President & CEO Dr. Ron Kurtz, CFO Shelley Thunen, and VP IR Oliver Moravcevic. Top takes: 1) LDD and LAL adoption remains in the early stages in the US; 2) RXST isn't seeing pushback on premium price; 3) Competition isn't likely to materialize in the next 5 years; 4) GM should continue to expand. We continue to believe the LT trajectory remains very attractive, esp with OUS approvals coming soon. for LDD There are ~10K ophthos in the US performing cataract surgery, with ~4K high-vol ones responsible for ~60% of the vols. RXST has trained ~1.5K, with an install base of ~1K, and thinks LALs should be offered to all cataract patients.
Oppenheimer
$72→$65
Buy
332.18%
Upside
Assigned
08/06/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$15
Hold
-0.27%
Downside
Reiterated
06/05/25
The overall stock score is primarily influenced by financial performance, with strong revenue growth offset by profitability and cash flow challenges. Technical analysis indicates a bearish trend, while valuation is hindered by ongoing losses and no dividend yield. Despite positive customer sentiment and European regulatory approval, revised revenue guidance lowers near-term outlook.
Wells Fargo
$25
Buy
66.22%
Upside
Reiterated
05/30/25
Piper Sandler
$18
Hold
19.68%
Upside
Reiterated
05/08/25
Bank of America Securities
$22→$18
Sell
19.68%
Upside
Reiterated
05/08/25
Needham
$22
Buy
46.28%
Upside
Reiterated
05/08/25
Stifel Nicolaus
$28→$17
Hold
13.03%
Upside
Reiterated
05/08/25
BTIG
$28
Buy
86.17%
Upside
Reiterated
05/07/25
UBS
$45→$16
Hold
6.38%
Upside
Downgraded
04/09/25
J.P. Morgan
$40→$17
Sell
13.03%
Upside
Downgraded
04/03/25
Morgan Stanley
$42
Buy
179.26%
Upside
Reiterated
04/03/25
Jefferies
$50
Buy
232.45%
Upside
Reiterated
03/03/25
Promising Growth and Competitive Edge: A Buy Rating for RxSightWe recently met with RXST management at their HQ, including President & CEO Dr. Ron Kurtz, CFO Shelley Thunen, and VP IR Oliver Moravcevic. Top takes: 1) LDD and LAL adoption remains in the early stages in the US; 2) RXST isn't seeing pushback on premium price; 3) Competition isn't likely to materialize in the next 5 years; 4) GM should continue to expand. We continue to believe the LT trajectory remains very attractive, esp with OUS approvals coming soon. for LDD There are ~10K ophthos in the US performing cataract surgery, with ~4K high-vol ones responsible for ~60% of the vols. RXST has trained ~1.5K, with an install base of ~1K, and thinks LALs should be offered to all cataract patients.
Oppenheimer
$72→$65
Buy
332.18%
Upside
Assigned
08/06/24
Best Analysts Covering RxSight
1 Month
xxx
Success Rate
14/24 ratings generated profit
Average Return
+6.49%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +6.49% per trade.
3 Months
xxx
Success Rate
13/24 ratings generated profit
Average Return
+11.18%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +11.18% per trade.
1 Year
Success Rate
14/24 ratings generated profit
Average Return
+49.42%
reiterated a buy rating last month
Copying David Saxon's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +49.42% per trade.
2 Years
xxx
Success Rate
11/26 ratings generated profit
Average Return
+41.02%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.31% of your transactions generating a profit, with an average return of +41.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RXST Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
5
6
7
5
7
Buy
8
6
7
7
4
Hold
3
6
5
9
9
Sell
0
0
0
2
3
Strong Sell
0
0
0
0
0
total
16
18
19
23
23
Each month's total comprises the sum of three months' worth of ratings.
RXST Financial Forecast
RXST Stock Forecast FAQ
What is RXST’s average 12-month price target, according to analysts?
Based on analyst ratings, RxSight’s 12-month average price target is 22.56.
What is RXST’s upside potential, based on the analysts’ average price target?
RxSight has 50.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RXST a Buy, Sell or Hold?
RxSight has a consensus rating of Hold which is based on 4 buy ratings, 3 hold ratings and 2 sell ratings.
What is RxSight’s price target?
The average price target for RxSight is 22.56. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $42.00 ,the lowest forecast is $16.00. The average price target represents 50.00% Increase from the current price of $15.04.
The highest analyst price target is $42.00 ,the lowest forecast is $16.00. The average price target represents 50.00% Increase from the current price of $15.04.
What do analysts say about RxSight?
RxSight’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of RXST?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.